January 9, 2024 News by Lindsey Shapiro, PhD CNM-Au8 leads to clinical gains for RRMS patients in extension study Daily treatment withĀ CNM-Au8 led to sustained improvements in vision and cognition for people with relapsing-remitting multiple sclerosis (RRMS), according to nearly three years of follow-up in the VISIONARY-MS trial and its open-label extension (OLE). Developer Clene Nanomedicine plans to present full trial results at the upcoming ACTRIMS…
December 19, 2023 News by Marisa Wexler, MS Talk therapy found to ease fatigue in MS – with or without follow-up A 20-week talk therapy program led to significant reductions in fatigue for people with multiple sclerosis (MS) ā benefits that were sustained to the end of the year-long trial regardless of whether patients participated in additional booster sessions. Such sessions were offered two and four months after the end…
October 16, 2023 News by Lindsey Shapiro, PhD ECTRIMS 2023: Tolebrutinib found to show benefits for up to 3 years Treatment with tolebrutinib for up to nearly three years was tied to low relapse rates, stable disability, and few new brain lesions among people with relapsing forms of multiple sclerosis (MS), according to new data from the long-term safety (LTS) extension of a Phase 2b trial. The data…
September 15, 2023 News by Andrea Lobo, PhD Benefits of long-term Tysabri seen in RRMS patients in Japan: Study Tysabri (natalizumab) significantly reduced the development of brain lesions on MRI scans in Japanese people with relapsing-remitting multiple sclerosis (RRMS), according to a new study. The therapy also eased or stabilized disability levels in most patients after five years of treatment, and significantly reduced the annual rate of…
August 2, 2023 News by Patricia Inacio, PhD Benefits of ketogenic diet in RRMS may be long lasting: Study Following a ketogenic diet ā one that’s low in carbohydrates and rich in fat ā for six months significantly reduced measures of body fat and fatigue, eased disease symptoms, and improved exercise capacity, cognition, and arm and hand dexterity in people with relapsing-remitting multiple sclerosis (RRMS), a study showed.
April 27, 2021 News by Forest Ray PhD #AANAM ā Mavenclad, for RRMS, Lowers Long-term Need for Other DMTs Editorās note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17ā22. GoĀ hereĀ to read the latest stories from the conference. A majority of theĀ relapsing-remitting multiple sclerosis (RRMS) patients givenĀ Mavenclad (cladribine) tablets in the CLARITY Phase 3 trial did…
November 23, 2020 News by Marta Figueiredo, PhD Early Use of Ocrevus Best for Slowing PPMS Progression, Long-term Data Show Early and continuous use ofĀ OcrevusĀ (ocrelizumab) significantly slows disability progression and delays the time until wheelchair reliance in people with primary progressive multiple sclerosis (PPMS), new Phase 3 data spanning more than six years show. Findings fromĀ the ORATORIO trial, comparing immediate use with a two-year delay, support Ocrevus’ sustained…
November 20, 2017 News by Iqra Mumal, MSc Fampyra/Ampyra May Improve Walking Speed in MS Patients Over Longer Term, Study Says Available long-term data on Fampyra (fampridine;Ā 4-aminopyridine)Ā suggest the treatment may improve walking speed in patients with multiple sclerosis (MS) for up to one year, but more research is needed, a French study reports. The study āMultiple Sclerosis and Clinical Gait Analysis before and after Fampridine: A Systematic Reviewā…